Catalent, Inc. (NYSE:CTLT - Get Free Report) SVP Joseph Anthony Ferraro sold 320 shares of the firm's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $59.97, for a total value of $19,190.40. Following the completion of the transaction, the senior vice president now owns 23,967 shares in the company, valued at approximately $1,437,300.99. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Catalent Price Performance
Shares of CTLT stock opened at $60.20 on Tuesday. Catalent, Inc. has a 12-month low of $31.80 and a 12-month high of $61.20. The firm has a market capitalization of $10.89 billion, a price-to-earnings ratio of -9.87, a price-to-earnings-growth ratio of 2.14 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The firm has a fifty day moving average of $60.13 and a 200-day moving average of $57.81.
Catalent (NYSE:CTLT - Get Free Report) last posted its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The firm had revenue of $1.30 billion during the quarter, compared to analysts' expectations of $1.23 billion. On average, equities research analysts forecast that Catalent, Inc. will post 0.95 earnings per share for the current year.
Institutional Trading of Catalent
[SHOCKING] Crypto Document Leak…
From Crypto 101 Media | Ad
The crypto market waits for no one.
And my team of experts and I believe that a BIG move is right around the corner.
That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.
Download your digital copy now
Large investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC boosted its holdings in shares of Catalent by 1.7% in the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company's stock valued at $619,000 after buying an additional 185 shares during the period. GAMMA Investing LLC lifted its position in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock valued at $58,000 after acquiring an additional 212 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in Catalent by 1.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company's stock worth $1,179,000 after purchasing an additional 220 shares during the period. Czech National Bank increased its holdings in Catalent by 0.7% during the 1st quarter. Czech National Bank now owns 31,801 shares of the company's stock worth $1,795,000 after purchasing an additional 228 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its stake in shares of Catalent by 3.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company's stock valued at $432,000 after purchasing an additional 278 shares during the period.
Analyst Upgrades and Downgrades
CTLT has been the subject of several analyst reports. Baird R W cut shares of Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. StockNews.com started coverage on shares of Catalent in a research note on Saturday, October 12th. They issued a "hold" rating on the stock. Robert W. Baird reiterated a "neutral" rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Royal Bank of Canada restated a "sector perform" rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Finally, William Blair reiterated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Nine analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $59.83.
Check Out Our Latest Report on CTLT
About Catalent
(
Get Free Report)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
